Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8JMNL)

• Drug Name: RG7155 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM8JMNL

Molecule-Related Drug Atlas

Drug(s) Targeting Colony stimulating factor-1 receptor (CSF-1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-382	DM0VGDC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
MCS-110	DM0CL4I	Bone metastases	2D50	Phase 2	[5]
JNJ-40346527	DM219SF	Hodgkin lymphoma	2B30	Phase 2	[6]
PD-360324	DM6F5EV	Rheumatoid arthritis	FA20	Phase 2	[7]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[8]
AMG 820	DMB6Q19	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
IMC-CS4	DMUYN26	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]

Drug(s) Targeting Macrophage colony-stimulating factor 1 (CSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emactuzumab	DM4W7Z0	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PLX73086	DMED2WN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
MSC110	DM6XC8H	Pigmented villonodular synovitis	FA27.1	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Colony stimulating factor-1 receptor (CSF-1R)	TT731LW	E9PEK4_HUMAN	Modulator	[2]
Macrophage colony-stimulating factor 1 (CSF1)	TT0IQER	CSF1_HUMAN	Antagonist	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035593)
• [2] Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Company report (Array)
• [5] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [6] An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
• [7] Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
• [8] Company report (Five Prime Therapeutics)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442.